Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 210

Related Citations for PubMed (Select 10363797)

1.

In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake.

Lewis JS, Srinivasan A, Schmidt MA, Anderson CJ.

Nucl Med Biol. 1999 Apr;26(3):267-73.

PMID:
10363797
3.

Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.

Sprague JE, Peng Y, Sun X, Weisman GR, Wong EH, Achilefu S, Anderson CJ.

Clin Cancer Res. 2004 Dec 15;10(24):8674-82.

4.

Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model.

Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, Morris MM, Miller JP, Anderson CJ.

Clin Cancer Res. 1999 Nov;5(11):3608-16.

6.

In vitro and in vivo evaluation of copper-64-octreotide conjugates.

Anderson CJ, Pajeau TS, Edwards WB, Sherman EL, Rogers BE, Welch MJ.

J Nucl Med. 1995 Dec;36(12):2315-25.

7.

DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.

Li WP, Lewis JS, Kim J, Bugaj JE, Johnson MA, Erion JL, Anderson CJ.

Bioconjug Chem. 2002 Jul-Aug;13(4):721-8.

PMID:
12121126
8.

Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.

Lewis JS, Laforest R, Lewis MR, Anderson CJ.

Cancer Biother Radiopharm. 2000 Dec;15(6):593-604.

PMID:
11190491
9.

64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.

Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW.

J Nucl Med. 2001 Feb;42(2):213-21.

10.

In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.

Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, Hoffman TJ.

J Nucl Med. 2007 Aug;48(8):1327-37. Epub 2007 Jul 13.

11.

Nuclear uptake and dosimetry of 64Cu-labeled chelator somatostatin conjugates in an SSTr2-transfected human tumor cell line.

Eiblmaier M, Andrews R, Laforest R, Rogers BE, Anderson CJ.

J Nucl Med. 2007 Aug;48(8):1390-6. Epub 2007 Jul 13.

12.

Targeting strategies for cancer radiotherapy.

Buchsbaum DJ, Rogers BE, Khazaeli MB, Mayo MS, Milenic DE, Kashmiri SV, Anderson CJ, Chappell LL, Brechbiel MW, Curiel DT.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3048s-3055s.

PMID:
10541342
13.

Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.

Hanaoka H, Tominaga H, Yamada K, Paudyal P, Iida Y, Watanabe S, Paudyal B, Higuchi T, Oriuchi N, Endo K.

Ann Nucl Med. 2009 Aug;23(6):559-67. doi: 10.1007/s12149-009-0274-0. Epub 2009 Jun 6.

PMID:
19504168
14.
15.

Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors.

Wadas TJ, Eiblmaier M, Zheleznyak A, Sherman CD, Ferdani R, Liang K, Achilefu S, Anderson CJ.

J Nucl Med. 2008 Nov;49(11):1819-27. doi: 10.2967/jnumed.108.054502. Epub 2008 Oct 16.

16.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

17.

Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats.

Anderson CJ, Jones LA, Bass LA, Sherman EL, McCarthy DW, Cutler PD, Lanahan MV, Cristel ME, Lewis JS, Schwarz SW.

J Nucl Med. 1998 Nov;39(11):1944-51.

18.

[99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results.

Maina T, Nock B, Nikolopoulou A, Sotiriou P, Loudos G, Maintas D, Cordopatis P, Chiotellis E.

Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):742-53. Epub 2002 Mar 23.

PMID:
12029547
19.
20.

Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer.

Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ.

Cancer Res. 2003 Oct 15;63(20):6864-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk